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ABSTRACT 
Background: The hypertensive disorders of pregnancy are a leading cause of maternal and 
perinatal mortality and morbidity. The ability to predict these complications using simple tests 
could aid in management and improve outcomes. We aimed to systematically review studies that 
reported on potential predictors of adverse maternal outcomes among women with a 
hypertensive disorder of pregnancy.  
Methods: We searched MEDLINE, Embase and CINAHL (inception - December 2016) for 
studies of predictors of severe maternal complications among women with a hypertensive 
disorder of pregnancy. Studies were selected in a two-stage process by two independent 
reviewers, excluding those reporting only on adverse fetal outcomes. We extracted data on study 
and test(s) characteristics and outcomes. Accuracy of prediction was assessed using sensitivity, 
specificity, likelihood ratios and area under the receiver operating curve (AUROC). Strong 
evidence of prediction was taken to be a positive likelihood ratio >10 or a negative likelihood 
ratio <0.1, and for multivariable models, an AUROC ≥0.70. Bivariate random effects models 
were used to summarise performance when possible.  
Results: Of 32 studies included, 28 presented only model development and four examined 
external validation. Tests included symptoms and signs, laboratory tests and biomarkers. No 
single test was a strong independent predictor of outcome. The most promising prediction was 
with multivariable models, especially when oxygen saturation, or chest pain/dyspnea were 
included.  
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Conclusion: Future studies should investigate combinations of tests in multivariable models 
(rather than single predictors) to improve identification of women at high risk of adverse 
outcomes in the setting of the hypertensive disorders of pregnancy. 
Keywords: Hypertensive disorders of pregnancy, pre-eclampsia, prognosis, prediction, maternal 
complications, review  
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INTRODUCTION 
The hypertensive disorders of pregnancy (HDPs) complicate about 3-10% of pregnancies.1-31-3 
They are one of the major contributors to maternal and fetal mortality and morbidity globally, 
with approximately 30,000 maternal and 500,000 perinatal deaths attributed to the HDPs 
annually.2,4 Maternal complications include eclampsia, stroke, and damage to the hepatic and 
renal organs.2,5 Predicting the onset of these complications could aid in timely interventions such 
as increased surveillance, treatment of symptoms, transfer to higher care facility and delivery 
when necessary, which could reduce morbidity and mortality from the HDPs.6,7  
Maternal risk factors used as criteria for severity classification by some international clinical 
practice guidelines do not accurately identify women at high risk of developing maternal 
complications.8-11 While many studies have reported associations between certain biomarkers 
and adverse outcomes,12-15 only a few studies have examined the accuracy of these tests in 
predicting adverse maternal outcomes; in other words, the accuracy of discriminating women 
who do experience serious morbidities versus those who do not at the individual level. The tests 
reported in these studies range from single markers to multiple markers combined in prediction 
models. Prediction models are increasingly used in clinical practice since they have the 
advantage of combining various factors to potentially provide more accurate predictions.16 
Regardless of the prediction method used, there is a need for the results from these studies be 
summarised and compared to determine if they give meaningful and accurate information to 
assist clinicians in the management of the HDPs. 
Several systematic reviews have assessed the predictive ability of individual variables such as 
uric acid, maternal symptoms, and liver function tests for maternal and fetal complications 
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resulting specifically from pre-eclampsia.17-20 To our knowledge, there have been no reviews 
assessing predictors for maternal complications resulting from all types of HDPs. This broader 
disease definition is important, as other HDPs still contribute substantially to the burden of the 
disease.2,10,21 In addition, these reviews were conducted between 2006 and 2011 and since then 
the definition for HDPs, particularly pre-eclampsia, has evolved.3 Furthermore, the studies 
included in these reviews solely assessed potential univariable predictors, thus the need to also 
review potential predictors combined in multivariable models. Therefore, we aimed to 
systematically review studies reporting the predictive ability, for both single and combined 
markers, of adverse maternal outcomes in women with HDPs. 
METHODS 
Protocol and registration 
A protocol for this review has been registered on PROSPERO (registration number: 
CRD42017054328). 
Eligibility criteria 
The population of interest was women with a HDP: pre-eclampsia, gestational hypertension, or 
chronic (pre-existing) hypertension, as defined by the study (with study definitions documented). 
The predictors of interest were any tests measured to predict adverse maternal outcomes from 
HDP. The adverse maternal outcomes considered were severe complications from the HDPs 
which had been agreed upon in a Delphi Consensus in the PIERS (Pre-eclampsia Integrated 
Estimates of RiSks study) (https://pre-empt.cfri.ca/monitoring/fullpiers );7 in addition, 
postpartum haemorrhage (PPH) and disseminated intravascular coagulation (DIC) were 
considered as these outcomes have been subsequently reported to be strongly linked with 
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HDPs.21  Detailed inclusion and exclusion criteria and full list of outcomes of interest are shown 
in Appendix S1. 
Search and selection Strategy 
We searched MEDLINE (Ovid), Embase (Ovid), CINAHL (EBSCO), and EBM Reviews (Ovid) 
Library databases from their inception to December 2016. We also searched Google Scholar and 
grey literature sources (such as University of British Columbia cIRcle, government websites, 
etc.) for other potential articles. Web of Science was used for citation tracking of review and 
eligible articles and the reference lists of studies selected for inclusion were scanned to capture 
any articles that were not identified through the electronic search. The search terms included 
both subject headings terms and key words related to the HDPs, with methodological filters to 
identify prognostic test studies for maternal complications (Appendix S2). 
All retrieved articles were screened independently for eligibility by two reviewers (UVU and 
DAD), first by title and abstract and then, by reviewing the full articles. Final selections were 
compared and any conflicts resolved by discussion and/or by a third reviewer (BP). 
The predictive measures used were sensitivity, specificity, likelihood ratios (LRs), and area 
under the receiver operating characteristic curve (AUROC). Studies that reported none of these 
predictive measures were included only if adequate data were provided to calculate these 
measures. We excluded studies reporting both maternal and fetal outcomes as a combined 
outcome except in cases where the test prediction performance for the maternal outcomes could 
be separated. We also excluded studies that included any of the HDPs as one of the outcomes. 
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Data extraction and assessment of study quality 
For each eligible study, information on population characteristics, tests used as predictors, 
measures and accuracy of prediction were extracted by one reviewer (UVU) and reviewed by 
another (DAD). Methodological quality assessment of the included studies was carried out using 
the QUIPS (Quality in Prognostic Studies) tools,22 which have been validated and also used in 
similar studies.23 The relevant study aspects that were scrutinized included methods of sampling 
and recruitment, adequate description of tests and outcomes, complete follow-up or handling of 
missing data explained, and sample size. In total, there were eight questions considered and one 
point was awarded for each assessment question that was met. In addition, studies reporting 
multivariable prediction models were assessed for internal and external validation. We 
considered studies with a total score of ≥ 7 as having a low risk of bias, 4-6 as medium risk of 
bias, and <4 as high risk of bias.   
Data synthesis 
We constructed 2×2 tables for each included study cross-classifying test results and the 
occurrence of adverse maternal outcomes. Measures of predictive performance were sensitivity, 
specificity, LRs, predictive values, and AUROC. These measures were either retrieved directly 
from the studies or calculated from constructed from raw data and 2×2 tables. LRs were used to 
provide interpretations for clinical usefulness as a measure that is independent of disease 
prevalence; for positive LRs (LR+), an LR of 5-10 and >10 were interpreted as having moderate 
and strong evidence to ‘rule in’ the disease respectively while for negative LRs (LR-), an LR of 
0.1-0.2 and <0.1 were interpreted as having moderate and strong evidence to ‘rule out’ the 
disease respectively.24 An AUROC ≥0.70 was also considered to reflect good discriminatory 
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ability for multivariable models.25 Wherever possible, meta-analyses were conducted for similar 
tests predicting similar outcomes and having 3 or more 2×2 tables. Meta-analyses were 
performed using a bivariate meta-regression model, which uses a random effects approach, to 
calculate pooled estimates of the likelihood ratios.26-28  
All statistical analyses were performed using R version 3.1.3 (The R Project for Statistical 
Computing). 
RESULTS 
Literature Search and identification results 
Figure 1 summarizes article identification and selection. Of 2137 articles retrieved, we included 
32 primary articles. Important exclusions presented an outcome that either included but were not 
restricted to women with a HDP (N=6), presented combined maternal and fetal outcomes 
(N=12), or studies for which a 2*2 table could not be constructed in order to calculate the 
diagnostic tests characteristics of interest (N=3) (see Appendix S3 for excluded references).   
Characteristics of included studies 
Characteristics of the included studies are presented in Appendix S4. In brief, included articles 
were published between 1988 and 2017. Eleven were multicentre and 21 from single centres. 
Most studies (30/32) were cohort in design, usually prospective (24/30); one was a randomized 
trial and another was a case-control study. The countries where data were collected included 
Australia (N=8), the United Kingdom (N=8), Canada (N=7), New Zealand (N=7), USA (N=7), 
South Africa (N=5), India (N=3), The Netherlands (N=2), Pakistan (N=2), and one each of Iran, 
Spain, Tunisia, Turkey, Uganda, Mexico and Brazil.  
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In total, the number of independent women in the included studies was 9,360, with a mean or 
median gestational age at admission or recruitment ranging from 23 weeks to 36 weeks. The 
mean maternal age ranged from 23 to 35 years old, and 13% to 89% were nulliparous.  
All included studies were published in English except for one study that was in French. Four 
studies presented external validation of a study. 
Definition of HDPs 
Four studies included women diagnosed with chronic hypertension; four studies also included 
gestational hypertension while the remaining studies reported solely on women with pre-
eclampsia (including HELLP syndrome) or/and superimposed pre-eclampsia. Chronic 
hypertension was defined as high blood pressure (≥140/90 mmHg) before pregnancy or at <20 
weeks gestation, and gestational hypertension as high blood pressure at ≥20 weeks gestation 
across all the studies; however, the definition of pre-eclampsia varied by the reference guideline 
used: the International Society for the Study of Hypertension in Pregnancy (ISSHP) (N=9),29 
American Congress of Obstetricians and Gynecologists (ACOG) (N=8),30 National Institute for 
Health and Clinical Excellence (NICE) (N=1),9 Society of Obstetricians and Gynaecologists of 
Canada (SOGC) (N=13),3 or National High Blood Pressure Education Program (NHBPEP) 
(N=1)31 guidelines.. Some studies also specifically mentioned the severity of the HDP such as 
severe pre-eclampsia,32-38 early-onset pre-eclampsia,33,38 or mild chronic hypertension33 
(Appendix Table S4). 
Quality of studies  
The quality of the included studies is summarised in Figure 2 and Appendix S5. The studies 
scored well with respect to adequacy of population selection description, appropriateness of the 
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patient spectrum/representativeness, and adequacy of test and outcome descriptions. However, of 
the 32 studies, only 14 mentioned complete follow up or explained withdrawals, 11 reported on 
handling of missing data, six reported sample size calculations, and two of five multivariable 
model studies reported both internal and external validation; all four external validation studies 
were classified as having a medium to high risk of bias. As a result, only eight studies were 
ranked as being at low risk of bias, 22 at medium risk, and two at high risk. 
Predictors, outcomes and data synthesis 
The predictors reported in the studies included demographics and pregnancy characteristics (e.g., 
gestational age), maternal signs and symptoms of pre-eclampsia [including oxygen saturation 
(SpO2)], urinary protein excretion, laboratory abnormalities associated with pre-eclampsia, 
and/or biomarkers (Table 1). 
The prevalence of adverse maternal outcomes ranged from 1.1% to 34.2%. Nine studies reported 
on single outcomes, most commonly eclampsia (N=6), and placental abruption (N=6). Most 
studies (23/32) reported on composite outcomes; these usually included the common single 
outcomes as well as thrombocytopenia, PPH, ascites and hepatic rupture.  
The 32 studies resulted in 74 2×2 tables. Table 1 presents the sensitivities, specificities, 
likelihood ratios, and AUROCs for the predictor variables. We were unable to perform meta-
analysis on the majority of predictors evaluated. The only predictor meeting our a priori criteria 
for meta-analysis, specifically having 3 published reports of effect using a similar outcome type, 
was  the sFlt1/PlGF ratio for the prediction of composite maternal outcomes.  
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Univariable predictors 
Signs and symptoms  
In the univariable analyses, the maternal symptoms39-42 evaluated were: headache (N=3 studies), 
visual disturbance (N=3), nausea or vomiting (N=2), right upper quadrant pain or epigastric pain 
(N=2), chest pain or dyspnoea (N=2), abdominal pain and vaginal bleeding (N=1), and 
hyperreflexia (defined as “vivid” deep tendon reflexes) or “non-specific viral symptoms” (not 
defined) (N=1 study each). The signs evaluated were oxygen saturation (N=1), and BP 
[N=3].40,43-44.  
Only non-specific viral symptoms had moderate LR+ for ruling in composite adverse maternal 
outcomes39 while headache, visual symptoms and hyperreflexia each had moderate LRs (-) for 
ruling out eclampsia (LRs between 0.1 and 0.2).40 Non-specific viral symptoms and oxygen 
saturation of <93% also had reported AUROCs of ≥0.7 suggesting good discriminatory ability 
for the prediction of composite adverse maternal outcomes. The usefulness of each of these 
symptoms was demonstrated in only one study. 
Blood pressure 
One of the signs evaluated was blood pressure, which was assessed in three studies40,43-44 as 
systolic (N=2), diastolic (N=1), or mean arterial pressure (MAP, N=1). The outcomes being 
predicted in these studies were eclampsia and placental abruption, for women with either pre-
eclampsia or mild chronic hypertension. The cut-off for SBP evaluated were >140 and ≥ 160 
mmHg40,43 while the cut-off for DBP was > 90 mmHg;43 MAP was assessed at > 105 mmHg.44 
Although significant associations (p-values <0.05) between blood pressure and adverse outcomes 
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were presented in these studies, none of them showed a clinically useful measure for blood 
pressure as a prognostic test for adverse maternal outcomes. 
Proteinuria 
Proteinuria was assessed in six studies,40,45-49 using measurements of 24h urinary protein 
excretion (N=5), spot protein/creatinine ratio (N=1), spot albumin/creatinine ratio (N=1) and/or 
urinary dipstick testing (N=3).  
Only the study by Bouzari et al45 reported a moderate LR-  for ruling out placental abruption 
using 24-hour urine proteinuria, at a cut-off of 1750mg [LR-  of 0.1 (95% CI: 0.0–0.6)] with an 
AUROC of 0.78. No other study reported a clinically useful measure for ruling in or out adverse 
maternal outcomes using proteinuria testing. 
Laboratory tests 
The laboratory tests assessed were: platelet count (N=4 studies),39,44,50-51 serum creatinine 
(N=1),40 serum uric acid (N=3),40,53-54 international normalized ratio (INR, N=1),52 aspartate 
transaminase (AST, N=4),39-40,52,55 alanine transaminase (ALT, N=2),39,52 lactate dehydrogenase 
(LDH, N=2),39,52 serum albumin52 and total bilirubin52  (N=1 each). 
None of the laboratory tests had a useful LR+ to rule in adverse maternal outcomes. Only serum 
uric acid had a moderate LR- for ruling out eclampsia in one study (LR- of 0.1 (95% CIs: 0–
0.9).54 However, AST, ALT, and LDH were reported to have good discriminatory abilities, with 
AUROCs of >0.70 for prediction of adverse maternal outcome in the study by Kozic et al52 
Biomarkers 
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Placental growth factor (PlGF) only (N=1 study),56 soluble fms-like tyrosine kinase-1 (sFlt1) to 
PlGF ratio (N=4),57-60 and Neutrophil Gelatinase-Associated Lipocalin (NGAL, N=1)61 were 
evaluated as predictors. The study on PlGF alone was reporting on the prediction of PPH while 
the studies on sFlt1:PlGF ratio and NGAL were evaluating the prediction of composite adverse 
maternal outcomes. None of these biomarkers were reported to have clinically useful measures to 
either rule in or rule out adverse maternal outcomes. The meta-analysis for the sFlt1: PlGF ratio 
for predicting composite outcomes demonstrated poor pooled LRs:- LR+ 1.7 (95% CIs: 1.2–2.0)] 
and LR- of 0.6 (95% CIs: 0.5–0.8) (tau2 for heterogeneity=0). 
Multivariable predictors 
Six studies evaluated a combination of multiple variables to predict a composite of adverse 
maternal outcomes.42,62-65 Four of these multivariable studies were part of the PIERS studies: the 
fullPIERS model,7 miniPIERS model,62 extended miniPIERS model with SpO2,63 and a 
combined cardiorespiratory symptom model by Millman et al42 for the prediction of the PIERS 
composite outcome; the outcomes in the two other studies by Chan et al64 and Girling et al65 also 
included some components of the PIERS outcomes such as renal failure, thrombocytopenia, liver 
disease and pulmonary oedema. The miniPIERS model,62 and extended miniPIERS model with 
SpO2,63 were the only multivariable models that included women with all HDPs, while the others 
were for women with (super-imposed) pre-eclampsia. The most commonly used predictors in 
these models were chest pain and dyspnoea (N=4 models), oxygen saturation and gestational age 
(N=3), and AST (N=2). Three of the multivariable models (fullPIERS model,7 miniPIERS 
model,62 and extended miniPIERS model with SpO263) reported moderate to high LR+ for ruling 
in adverse maternal outcomes (LR+ of 5 and above) and four of them (models by Millman, 
fullPIERS model,7 miniPIERS model,62 extended miniPIERS model with SpO2) reported 
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AUROCs of ≥0.7; all of these were predicting PIERS adverse outcomes. The model with the 
highest AUROC was reported in the study by von Dadelszen et al7 (AUROC 0·88 (95% CI 
0·84–0·92) and also had the highest LR+ of 26.5 to strongly rule in composite adverse maternal 
outcomes. The multivariable model, called the fullPIERS model, included six variables: 
gestational age of disease onset, platelet count, serum creatinine, AST, chest pain or dyspnea and 
SpO2. For details of the model variable coefficients, please see Appendix S6.  
External validation 
Four studies on external validation were included.66-69 All assessed the fullPIERS model by von 
Dadelszen et al.7 AUROCs were >0.7 (N=2 studies)67-68 and 0.68 (95% CI 0·60–0·76) in the 
study by Hadley; AUROC was not reported in the study by Agrawal et al. Likelihood ratios were 
reported in only two studies and these studies reported moderate LRs (+) for ruling in adverse 
outcomes.66-67 Although all four studies were assessing the validity of the fullPIERS model, there 
were substantial differences between the fullPIERS and external validation populations, such as 
disease spectrum, setting, and management (Table S4b). Due to these case-mix differences, we 
refrained from pooling the results of these studies.  
DISCUSSION 
Main findings 
Our systematic review included 32 studies of women with HDPs that explored the ability of 
various tests to predict adverse maternal outcomes. There was substantial heterogeneity in the 
characteristics of the populations included in these studies and the outcomes used. This 
heterogeneity likely contributed to the inconsistent results found for the predictive performance 
of the evaluated tests. Overall, the univariable predictors that had moderate performance as a rule 
  
15 
 
in test were “non-specific viral symptoms” and 24hr urinary protein, and as rule-out tests were 
headache, visual symptoms, hyperreflexia, and serum uric acid. Non-specific viral symptoms, 
oxygen saturation <93%, AST, ALT, and LDH were the only univariable tests that had good 
discrimination with a reported AUROC of ≥ 0.7. However, these tests were either assessed in 
only one study (e.g. hyperreflexia and “non-specific viral symptoms”) or were evaluated in 
multiple studies but performed poorly in them. As such, individual tests were interpreted as 
lacking strong evidence of clinical usefulness. In addition, the definition of non-specific viral 
symptoms was not clearly stated in the study.39 
In our review, oxygen saturation showed the most promise as a prognostic test for the 
hypertensive mother in univariable and especially in multivariable models. Other tests to 
consider when combining variables in multivariable models include headache, visual symptoms, 
AST, chest pain or dyspnea and gestational age, based on their inclusion in well performing 
multivariable models, which had also been internally validated. However, the performance of the 
multivariable models may have been due to the presence of other possible good predictors in the 
models driving the effect (Appendix S6), thus, some of these tests (e.g. AST) may require 
further investigations as possible predictors for adverse maternal outcomes of HDPs.72  
The best performing multivariable model included gestational age, chest pain or dyspnoea, 
oxygen saturation, platelet count, creatinine and AST as predictors of composite maternal 
outcomes in women with pre-eclampsia and superimposed pre-eclampsia.7 This model was 
externally assessed in four studies that were included in this review. Although three of these 
validation studies showed a good discriminatory performance (AUROC >0.7), two of these 
studies were underpowered. In addition, there were case-mix differences between the studies and 
the development study which could have affected the model performance. 
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Comparison with literature and guidelines 
Except for one study on predicting eclampsia, our findings are similar to the study by 
Thangaratinam et al17 which reported that proteinuria was a poor predictor of maternal 
complications in pre-eclampsia based on the pooled positive and negative LRs in their study. 
Another review by Moris et al20 concluded that there was insufficient evidence to recommend 
proteinuria as a prognostic test for the prognosis of adverse maternal outcomes in pre-eclampsia. 
Proteinuria is also not recommended as a test for the prediction of adverse maternal outcomes for 
women with HDPs by ACOG, AOM, and SOGC guidelines; however, the NICE guideline calls 
for large high quality prospective studies to determine the best methods of measurement and 
threshold for predicting adverse outcomes.9 
In a systematic review of maternal symptoms as predictors of adverse outcomes,19 epigastric pain 
and visual disturbance were reported to be the most useful predictors based on their AUROCs; 
however, this was not the case in our review for epigastric pain. Also, contrary to the findings in 
the review by Koopmans et al70 and Thangaratinam et al,71 uric acid did not show any clinical 
usefulness in the prediction of maternal outcomes in our review except for eclampsia. 
Noteworthy is the difference between the inclusion criteria and outcomes of interest between 
these reviews and ours. In the reviews, HELLP syndrome was considered as an adverse outcome 
and was one of their most common outcomes; however, for our review, HELLP syndrome was 
one of our inclusion criteria for HDP because it has been recognised as part of the spectrum of 
pre-eclampsia rather than an outcome.30 Therefore, it is possible that the performances of 
epigastric pain and uric acid in these reviews were related to women with HELLP rather than 
predictive of adverse maternal outcomes that measure end-organ failure.  
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A review by Thangaratinam et al8 reported that liver enzyme tests (AST, ALT and LDH) were 
moderate predictors of combined maternal and fetal complications in women with pre-eclampsia. 
Although, AST, ALT and LDH did not have any strong clinical utility in univariable analyses 
based on LRs, their AUROCs in the individual studies suggested good discrimination and may 
therefore be considered for further investigation. This is also in line with the NICE guideline 
which recommends that more studies for kidney and liver function, and coagulation for the 
prediction of adverse outcomes are needed.9  
Strengths and limitations 
Our review is the first to review potential predictors of maternal complications among women 
with all types of HDPs. Including all HDPs improve the clinical applicability because it includes 
a broader population of women at risk and not all women initially present with pre-eclampsia at 
admission. We were able to systematically identify and collate the performance of possible 
predictors using updated definitions for HDPs and with no restrictions on language or year of 
publication. We ran our search terms again in July 2017 to ensure that we covered any recent 
eligible publications. Our review also included the use of multivariable models which have not 
been assessed in any previous review.  
The majority of the included studies in this review were deemed to be of low or moderate 
quality. Many of the studies were underpowered and some of the multivariable models were not 
externally validated; thus the results from these studies may not be applicable in a different 
setting or population. However, we did not exclude these studies because we were interested in 
reviewing any tests with potential maternal prognostic value for HDPs and also due to sparse 
literature in the study area. The only articles not included were ones that did not meet the 
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inclusion criteria for severe maternal outcomes; for example, we excluded a new prognostic 
study by Allotey et al73 which included preterm delivery are one of their composite maternal 
outcomes as we did thought that this qualified more as a perinatal than a maternal outcome. The 
methodological issues in the included studies and the heterogeneity in population characteristics 
affect our ability to draw any strong conclusions in our review. The limited numbers of studies 
evaluating similar tests and outcomes also made it impossible to synthesize most of the 
predictors using meta-analyses. 
CONCLUSION 
Prediction of adverse maternal outcomes from the HDPs is key to optimal management, 
including timing of delivery and planning the most appropriate place of care.4,15  Overall, the 
multivariable models performed better than the univariable tests. However, sufficiently-powered 
external validation studies using a similar population as the development studies are still required 
for most of these models. Our review highlights the need for better quality studies in prediction 
and supports the use of a combination of predictors for better chances of prediction of adverse 
maternal outcomes. 
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Table 1. Accuracy of tests in the prediction of adverse maternal outcomes in women with HDP, N = 32 studies 
 
UNIVARIABLE TESTS, N=24 studies 
Author, Year Test / cut-off Outcome Total 
(outcome 
rate %) 
Sensitivity 
(95% CI) 
Specificity  
(95% CI) 
LR+  
(95% CI) 
LR-  
(95% CI) 
AUROC 
(95% CI) 
Signs and/or symptoms 
Aziz et al. 2011  Headache Composite 74 (27%) 30.0  
(11.9-54.3) 
46.3  
(32.6-60.4) 
0.6  
(0.3-1.1) 
1.5  
(1.0-2.3) 
0.40  
(0.20-0.50) 
Ben Salem et al. 
2003 
Headache Eclampsia 120 (34.2%) 97.6 
(85.6-99.9) 
26.6 
(17.6-37.9) 
1.3 
(1.2-1.5) 
0.1 
(0-0.7) 
- 
Yen et al. 2011 Headache PIERS 
Composite 
2020 (7.1%) - - - - 0.535  
(0.47-0.58) 
Aziz et al. 2011 Vomiting Composite 74 (27%) 10.0  
(1.2-31.7) 
77.9  
(64.4-88.0) 
0.5  
(0.1-1.8)  
1.2  
(0.9-1.4) 
0.40  
(0.30-0.50) 
Yen et al. 2011 Nausea/vomiting PIERS 
Composite 
2020 (7.1%) - - - - 0.54  
(0.48-0.60) 
Ben Salem et al. 
2003 
Visual symptoms Eclampsia 120 (34.2%) 85.4 
(70.1-93.9) 
65.8 
(54.2-75.9) 
2.5 
(1.8-3.5) 
0.2 
(0.1-0.5) 
- 
Yen et al. 2011 Visual symptoms PIERS 
Composite 
2020 (7.1%) - - - - 0.50  
(0.45-0.56) 
Yen et al. 2011 Abdominal pain or 
vaginal bleeding 
PIERS 
Composite 
2020 (7.1%) - - - - 0.57 
(0.47-0.67) 
Aziz et al. 2011 Epigastric pain Composite 74 (27%) 10.0  
(1.2-31.7) 
70.4  
(56.4-82.0) 
0.3  
(0.1-1.3) 
1.3  
(1.0-1.6) 
0.4  
(0.3-0.5) 
Yen et al. 2011 RUQ or epigastric 
pain 
PIERS 
Composite 
2020 (7.1%) -  - - - 0.605 
(0.545-
0.664) 
Millman et al. 
2011 
Chest pain and/or 
dyspnoea 
PIERS 
Composite 
1534 (6.1%) - - - - 0.59  
(0.52-0.65) 
Millman et al. 
2011 
Chest pain and/or 
dyspnoea 
Non-
respiratory 
PIERS 
Composite 
1534 (4.4%) - - - - 0.53  
(0.45-0.60) 
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Yen et al. 2011 Chest pain or 
dyspnoea 
PIERS 
Composite 
2020 (7.1%) - - - - 0.58  
(0.52-0.64) 
Millman et al. 
2011 
SpO2 <93% PIERS 
Composite 
1534 (6.1%) - - - - 0.71  
(0.65-0.77) 
Millman et al. 
2011 
SpO2 <93% Non-
respiratory 
PIERS 
Composite 
1534 (4.4%)     0.64  
(0.57-0.71) 
Aziz et al. 2011 Non-specific viral 
symptoms 
Composite 74 (27%) 65.0  
(40.8-84.6) 
87.0  
(75.1-94.6) 
5.0  
(2.3-10.7) 
0.4  
(0.2-0.7) 
0.80 
(0.60-0.90) 
Ben Salem et al. 
2003 
Vivid deep tendon 
reflexes 
Eclampsia 120 (34.2%) 97.6 
(85.6-99.9) 
46.8 
(35.6-58.3) 
1.8 
(1.5-2.3) 
0.1 
(0.0-0.4) 
- 
Blood pressure (BP) 
Ben Salem et al. 
2003 
sBP ≥ 160 mmHg Eclampsia 120 (34.2%) 92.7 
(79.0-98.1) 
24.1 
(15.4-35.2) 
1.2 
(1.0-1.4) 
0.3 
(0.1-1.0) 
- 
Ankumah  et al. 
2014 
sBP and/or dBP 
>140/90 mmHg 
Placental 
abruption 
759 (1.4%) 36.4  
(12.4-68.4) 
62.8  
(59.2-66.3) 
1.0 
(0.4–2.1) 
1.0 
(0.6–1.9) 
- 
Witlin et al. 1999 MAP >105 mmHg Eclampsia 
 
445 (9.0%) 92.5 
(78.5-98.0) 
3.2 
(1.8-5.6) 
1.0 
(0.9–1.0) 
2.3 
(0.9–8.0) 
- 
 
Witlin et al. 1999 MAP >105 mmHg Placental 
abruption 
445 (7.2%) 87.5 
(70.1-95.9) 
2.2 
(1.1-4.2) 
0.9 
(0.8–1.0) 
5.7 
(1.9–17.8) 
- 
Proteinuria 
Ben Salem et al. 
2003 
Dipstick >3+ Eclampsia 120 (34.2%) 85.3 
(70.1-93.9) 
53.2 
(41.7-64.4) 
1.8 
(1.4-2.4) 
0.3 
(0.1-0.6) 
- 
Ben Salem et al. 
2003 
24h urine >3g/d Eclampsia 120 (34.2%) 36.6 
(22.6-53.1) 
91.1 
(82.0-96.1) 
4.1 
(1.8-9.3) 
0.7 
(0.6-0.9) 
- 
Bouzari et al. 2014 
 
24h urine >1.75g/d Placental 
abruption 
289 (5.9%) 94.1 
(69.2-99.7) 
63.7 
(57.5-69.3) 
2.6 
(2.1–3.1) 
0.1 
(0.0–0.6) 
0.777 
Gangaram et al. 
2009† 
Spot urine ACR 
≥300mg/g  
Composite  
 
155 (2.6%) 0 
 
55.0 
(46.7-63.0)  
- 
 
1.8 
(1.8-1.8) 
 
Hall et al. 2002 24h urine increased 
by ≥2g 
Placental 
abruption 
74 (13.5%) 30.0 
(8.1-64.6) 
59.4 
(46.4-71.2) 
0.7 
(0.3-2.0) 
1.2 
(0.8-1.8) 
- 
Hall et al. 2002 24h urine increased 
by ≥2g 
Ascites 74 (10.8%) 62.5 
(25.9-89.8) 
63.6 
50.8-74.9) 
1.7 
(0.9-3.2) 
0.6 
(0.2-1.5) 
- 
 
Hall et al. 2002 24h urine increased 
by ≥2g 
Pulmonary 
edema† 
74 (1.4%) 0 
(0-94.5%) 
60.3 
(48.1-71.3) 
- 
 
1.7 
(1.6-1.7) 
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Hall et al. 2002 24h urine increased 
by ≥2g 
Eclampsia† 74 (1.4%) 100 
(5.5-100) 
61.6 
(49.5-72.6) 
2.6 
(1.9-3.5) 
- 
 
- 
Payne et al. 2011 Dipstick PIERS 
Composite 
2002 (5.3%) - - - - 0.55  
(0.49-0.61) 
Payne et al. 2011 Spot urine PRCR PIERS 
Composite 
2002 (5.3%) - - - - 0.48  
(0.42-0.55) 
Payne et al. 2011 24hr urine PIERS 
Composite 
2002 (5.3%) - - - - 0.55  
(0.47-0.63) 
Schiff et al. 1996 24h urine increased 
by ≥2g 
Placental 
abruption 
2002 (5.3%) 40 
(7.3-83.0) 
63.9 
(50.6-75.5) 
1.1 
(0.4-3.4) 
0.9 
(0.5-2.0) 
- 
Laboratory tests 
Aziz et al. 2011 
2011 
Platelets  
≤100 × 105/L 
Composite 74 (27%) 70.0  
(45.7-88.1)  
20.4  
(10.6-33.5) 
0.9  
(0.6-1.2) 
1.5  
(0.6-3.4) 
0.40 
(0.30-0.60) 
Laskin et al. 2011 Platelets  
≤100 × 109/L 
PIERS 
Composite 
1405 (10.8%) 15.8 
(10.6-22.8) 
92.2 
(90.5-93.6) 
2.0 
(1.3–3.1) 
0.9 
(0.9–1.0) 
- 
Witlin et al. 1999 Platelets 
<60,000/mm3 
Placental 
abruption 
445 (7.2%) 37.5 
(21.7-56.3) 
85.0 
(81.1-88.2) 
2.5 
(1.5–4.1) 
0.7 
(0.6–1.0) 
- 
Yucesoy et al. 
2005 
Platelets 
<50,000/mm3 
Eclampsia 
 
44 (29.5%) 38.5 
(15.1-67.7) 
64.5 
(45.4-80.2) 
1.1 
(0.5–2.5) 
1.0 
(0.6–1.5) 
- 
 
Yucesoy et al. 
2005 
Platelets 
<50,000/mm3 
Placenta 
abruption  
44 (11.4%) 40.0 
(7.3-83.0) 
64.1 
(47.1-78.3) 
1.1 
(0.4–3.5) 
0.9 
(0.4–2.0) 
- 
Yucesoy et al. 
2005 
Platelets 
<50,000/mm3 
Disseminated 
intravascular 
coagulation 
44 (18.2%) 75.0 
(35.6-95.5) 
72.2 
(54.6-85.2) 
2.7 
(1.4–5.2) 
0.3 
(0.1–1.2) 
- 
Yucesoy et al. 
2005 
Platelets 
<50,000/mm3 
Acute renal 
failure 
44 (15.9%) 71.4 
(30.3-94.9) 
70.3 
(52.8-83.6) 
2.4 
(1.2–4.8) 
0.4 
(0.1–1.3) 
- 
Yucesoy et al. 
2005 
Platelets 
<50,000/mm3 
Maternal 
mortality 
44 (9.1%) 25.0 
(1.3-78.1) 
62.5 
(1.3-76.8) 
0.7 
(0.1–3.8) 
1.2 
(0.6–2.2) 
- 
Kozic et al. 2011 INR PIERS 
Composite 
2008 (5.1%) - - - - 0.65  
(0.58-0.71) 
Ben Salem et al. 
2003 
Creatinine 
>100µmol/L 
Eclampsia 120 (34.2%) 39.0 
(24.6-55.5) 
81.0 
(70.3-88.6) 
2.1 
(1.1-3.7) 
0.8 
(0.6-1.0) 
- 
Ben Salem et al. 
2003 
Uric acid  
≥350 µmol/L 
Eclampsia 120 (34.2%) 82.9 
(67.4-92.3) 
65.8 
(54.2-92.3) 
2.4 
(1.7-3.4) 
0.3 
(0.1-0.5) 
- 
Livingston et al. 
2014 
Uric acid 
>345 µmol/L 
PIERS 
Composite 
1487 (13.3%) 80.2  
(70.8- 87.6) 
28.2  
(25.9-30.7) 
1.1 
(1.0–1.2) 
0.7 
(0.5–1.0) 
0.62 
(0.56-0.69) 
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Yassaee et al. 
2003† 
Uric acid ≥6mg/dL Maternal 
mortality† 
103 (8.7%) 100 
(62.9-100) 
53.2 
(42.6-63.4) 
2.1 
(1.7–2.7) 
0 
 
- 
 
Yassaee et al. 
2003† 
Uric acid ≥6mg/dL Eclampsia 103 (12.6%) 92.3 
(62.1-99.6) 
54.4 
(43.6-64.9) 
2.0 
(1.5–2.7) 
0.1 
(0–0.9) 
- 
Aziz et al. 2011 ALT ≥70 IU/L Composite 74 (27%) 55.0  
(31.5-76.9)  
25.9  
(15.0-39.7) 
0.7  
(0.5-1.1) 
1.7  
(0.9-3.4) 
0.4  
(0.3-0.5) 
Kozic et al. 2011 ALT PIERS 
Composite 
2008 (5.1%) - - - - 0 .73 
(0 .67-0.79) 
Aziz et al. 2011 AST ≥70 IU/L Composite 74 (27%) 60.0  
(36.1-80.9) 
42.6  
(29.2-56.8) 
1.1  
(0.7-1.6) 
0.9  
(0.5-1.8) 
0.50  
(0.40-0.60) 
Ben Salem et al. 
2003 
AST >30 IU/L Eclampsia 120 (34.2%) 63.4 
(46.9-77.4) 
70.9 
(59.4-80.3) 
2.2 
(1.4-3.3) 
0.5 
(0.4-0.8) 
- 
Kozic et al. 2011 AST PIERS 
Composite 
2008 (5.1%) - - - - 0.73  
(0.67-0.79) 
Romero et al. 1988 AST 2SD above 
mean 
Pulmonary 
edema 
275 (1.1%) 66.7 
(12.5-98.2) 
79.4 
(74.0-84.0) 
3.2 
(1.4–7.5) 
0.4 
(0.1–2.1) 
- 
 
Romero et al. 1988 AST 2SD above 
mean 
Eclampsia 275 (2.5%) 71.4 
(30.3-94.9) 
80.2 
(74.8-84.7) 
3.6 
(2.1–6.1) 
0.4 
(0.1–1.2) 
- 
Aziz et al. 2011 LDH ≥600 IU/L Composite  
 
74 (27%) 75.0  
(50.9-91.3)  
55.6  
(41.4-61.9) 
1.7  
(1.1-2.5) 
0.5  
(0.2-1.0) 
0.7  
(0.6-0.8) 
Kozic et al. 2011 LDH PIERS 
Composite 
2008 (5.1%) - - - - 0.74  
(0.68-0.81) 
Kozic et al. 2011 Serum albumin PIERS 
Composite 
2008 (5.1%) - - - - 0.63  
(0.57-0.69) 
Kozic et al. 2011 Total bilirubin PIERS 
Composite 
2008 (5.1%) - - - - 0.68  
(0 61-0.74) 
Biomarkers 
Ghosh et al. 2012 Serum PlGF 
<122pg/mL 
Postpartum 
hemorrhage 
(PPH) 
766 (8.7%) 73.1  
(60.7-82.9)  
76.7  
(73.3-79.7)  
3.14  
(2.57-3.82)  
0.35  
(0.24-0.52)  
- 
Leaños-Miranda et 
al. 
2013 
Serum sFlt-1/PlGF 
ratio ≥871 
Composite 
 
501 (9.6%) 
 
52.1  
(37.4-66.5) 
77.9  
(73.8-81.6) 
2.36  
(1.71-3.26) 
0.61 
(0.46-0.83) 
- 
Palomaki et al. 
2015 
Serum Flt-1/PlGF 
ratio >85 
Composite  237 (8.9%) 61.9 
(38.7–81.0) 
69.4 
(62.8–75.4) 
2.0 
(1.4–3.0) 
0.5 
(0.3–1.0) 
- 
Rana et al. 2013† Serum Flt-1/PlGF Composite 97 (8.2%) 100 51.7 2.1 ∞ - 
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ratio≥85  (59.7–100) (40.9–62.3) (1.7–2.6) 
Saleh et al. 2016† Serum Flt-1/PlGF 
ratio≥85 
Composite 
 
62 (9.7%) 100 
(51.7–100) 
10.7 
(4.4–22.6) 
1.1 
(1.0–1.2) 
- 
 
- 
Scazzochio et al. 
2013 
Maternal NGAL 
>100ng/mL 
Composite 67 (17.9%) 41.7  
(16.5-71.4) 
65.5  
(51.3-77.4) 
1.2  
(0.6-2.6) 
0.9  
(0.5-1.5) 
- 
MULTIVARIABLE TESTS, N=6 studies 
Chan et al.† 2005 Spot urine PRCR 
>500 and maternal 
age >35 years 
Composite 321 (34%) 10.2 
(5.4–17.9) 
100 
(97.8–100) 
- 0.9 
(0.8–1.0) 
0.67  
(0.55-0.71) 
Girling et al. 
1997† 
AST 30 U/L 
ALT 32 U/L 
Bilirubin 14 U/L 
GGT 41 U/L 
Composite 35 (20%) 100 
(56.1-100) 
57.1 
(37.4-75.0) 
2.3 
(1.5–3.6) 
- - 
Millman et al. 
2011 
Chest pain and/or 
dyspnoea and SpO2  
PIERS 
Composite 
1534 (6.1%) - - - - 0.73 
(0.67-0.78) 
Payne et al. 2014 miniPIERS model ǂ 
25% predicted 
probability 
PIERS 
Composite 
2081 (12.5%) 41.4 
(35.4–47.6) 
91.9 
(90.5–93.1) 
5.1 
(4.1–6.3) 
0.6 
(0.6–0.7) 
0.79  
(0.74–0.80) 
Payne et al. 2015 miniPIERS model ǂ 
and SpO2, 25% 
predicted 
probability 
PIERS 
Composite 
852 (17.3%) 49.6 
(40.3–58.8) 
91.5 
(89.2–93.4) 
5.9 
(4.3–7.9) 
0.6 
(0.5–0.7) 
0.81  
(0.76-0.86) 
von Dadelszen et 
al. 2011 
GA, chest pain or 
dyspnea, SpO2, 
platelet count, 
creatinine and AST; 
30% predicted 
probability 
PIERS 
Composite 
2023 (5%) 44.9 
(34.5–55.3) 
98.4 
(97.6-98.9) 
26.5 
(17.4–
40.2) 
0.6 
(0.5–0.7) 
0.88  
(0.84–0.92) 
EXTERNAL VALIDATION STUDIES, N=4 studies 
Agrawal et al. 
2015 
30% predicted 
probability 
PIERS 
composite 
322 (18.3%) 25.0 
(15.1–38.1) 
95.4 
(91.9–97.5) 
17.5  
(8.52-36.1) 
0.8 
(0.7–0.9) 
- 
Akkermans et al.  
2014 
30% predicted 
probability 
PIERS 
composite  
216 (14.8%) 81.3 
(63.0–92.1) 
98.4 
(94.9–99.6) 
49.8 
(16.0–
155.0) 
0.2 
(0.1–0.4) 
0.97 
(0.94–0.99) 
Hadley et al.  
2016* 
- PIERS 
composite 
503 (12.3%) - - - - 0.68  
(0.60-0.76 
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Ukah et al.  
2015 
30% predicted 
probability 
PIERS 
composite 
757 (14.0%) 45.0  
(0.36–0.55) 
92.4 
(84.9–99.9) 
5.9  
(4.2–8.4) 
0.2  
(0.1–0.5) 
0.77  
(0.72–0.82) 
† contains some zero cells; * Abstract only ; ǂ miniPIERS includes parity, gestational age, chest pain/dyspnea, headache or visual symptoms, 
vaginal bleeding with abdominal pain; sBP, and dipstick proteinuria 
ACR (albumin:creatinine ratio); AUROC (Area under the receiver operating characteristic curve); dBP (diastolic blood pressure); GA 
(gestational age); INR (international normalized ratio); LR+ (Positive likelihood ratio); LR- (Negative likelihood ratio); MAP (mean arterial 
pressure); NGAL (neutrophil gelatinase-associated lipocalin); PIERS (pre-eclampsia integrated estimate of risk); PRCR (protein:creatinine 
ratio); RUQ (Right upper quadrant pain); sBP (systolic blood pressure); SD (standard deviation); SpO2 (oxygen saturation) 
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ONLINE SUPPLEMENTS 
S1. Inclusion and exclusion criteria 
Selection criteria Inclusion Exclusion 
Population Studies recruiting patients with any 
hypertensive disorder of pregnancy 
(HDPs) – gestational hypertension, 
chronic hypertension, pre-
eclampsia, super-imposed pre-
eclampsia and HELLP syndrome   
Studies not recruiting women with 
HDP 
 
Intervention/ Study design Studies reporting risk prediction or 
prognosis tests for adverse 
maternal outcomes resulting from 
HDPs or studies that provide data 
that can be used to calculate these 
tests.  
 
Prognostic tests include at least one 
of the following: area under the 
receiver operating characteristic 
curve (AUROC), sensitivity, 
specificity, likelihood ratios, 
negative or positive predictive 
value. 
Studies that do not report prognosis 
tests OR 
studies not presenting sufficient 
data for calculation 
 
 
 
Comparators None 
 
 
Outcomes Primary outcome measures were 
studies including any PIERS 
adverse maternal outcomes 
(https://pre-
empt.cfri.ca/monitoring/fullpiers ) 
Studies without outcome measures 
OR 
Studies that report on combined 
fetal and maternal outcome and the 
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or/and Postpartum haemorrhage 
(PPH); disseminated intravascular 
coagulation (DIC) 
prediction of maternal outcome 
cannot be separated. 
 
Language   None   
Publication year limit  None  
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S2. Search strategy 
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1946 to Present> Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp Hypertension, Pregnancy-Induced/ (31573) 
 
2     (HDP or HDPs).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] (940) 
 
3     (preeclamp* or pre-eclamp*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] (35884) 
 
4     ((Chronic hypertens* or essential hypertens* or preexisting hypertens* or pre-existing hypertens*) adj3 (pregnan* or gestation*)).mp. [mp=title, abstract, 
original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier] (653) 
 
5     HELLP Syndrome/ (1609) 
 
6     HELLP.mp. (2473) 
 
7     or/1-6 (41093) 
 
8     nomograms/ (1952) 
 
9     Models, statistical/ (78055) 
 
10     logistic models/ (108873) 
 
11     "Predictive Value of Tests"/ (168044) 
 
12     Risk assessment/ (207143) 
 
13     clinical risk assessment*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] (302) 
 
14     prognos* model*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] (2879) 
 
15     predict* model*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] (20780) 
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16     (AUC or AUROC or area under the receiver or ROC or ROCs or Receiver operating curve*).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier] (96577) 
 
17     sensitivit*.mp. (935762) 
 
18     specificit*.mp. (926124) 
 
19     (LR* or likelihood ratio*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, unique identifier] (45658) 
 
20     negative predictive value*.mp. (34619) 
 
21     positive predictive value*.mp. (35114) 
 
22     or/8-21 (1990826) 
 
23     ((risk* or predict* or prognos*) adj6 (adverse or complication* or outcome* or event* or situation*)).mp. [mp=title, abstract, original title, name of 
substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique 
identifier] (286836) 
 
24     ((risk* or predict* or prognos*) adj6 (morbid* or mortality)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword 
heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier] (104862) 
 
25     ((risk* or predict* or prognos*) adj6 (Hepatic or GCS or Glasgow or Stroke or Cortical or RIND or retinal or Dialysis or renal or PIS or Positive inotropic 
support or Infusion or Myocardial or MI or Intubation or thrombocytop?nia)).mp. [mp=title, abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier] (128207) 
 
26     23 or 24 or 25 (466662) 
 
27     7 and 22 and 26 (828) 
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Appendix S3. Rejected Articles  
Combined HDP and outcome (N= 6) 
1. ElizaldeValdes V.M., TellezBecerril G.E., LopezAceves LJ. Construction and validation of a risk factor scale for complications of pre-eclampsia. Clinica e 
Investigacion en Ginecologia y Obstetricia 2016 01 Jul 2016;43(3):110-121 
2. Orabona R., Gerosa V., Gregorini M.E., Pagani G., Prefumo F., Valcamonico A., et al. The prognostic role of various indices and ratios of Doppler 
velocimetry in patients with pre-eclampsia. Clin.Exp.Hypertens. 2015 01 Feb 2015;37(1):57-62 
3. Tokmak A, Güney G, Aksoy RT, Guzel AI, Topcu HO, Keçecioglu TS, et al. May maternal anti-mullerian hormone levels predict adverse maternal and 
perinatal outcomes in preeclampsia? J MATERN FETAL NEONAT MED 2015 08;28(12):1451-1456 
4. Sak M.E., Evsen M.S., Soydinc H.E., Turgut A., Ozler A., Sak S., et al. Risk factors for maternal mortality in eclampsia: analysis of 167 eclamptic cases. 
Eur.Rev.Med.Pharmacol.Sci. 2012 Oct 2012;16(10):1399-1403 
5. Lumbanraja SN. Determining the maternal characteristics that predicts the adverse outcomes for patients with preeclampsia. Journal of Health and 
Translational Medicine 2013 2013;16(1):1-6 
6. tive value of urinary albumin: Creatinine ratio in pregnancy. Archives of Disease in Childhood: Fetal and Neonatal Edition 2014. June 2014;99:A137 
 
2*2 table not possible (N= 3) 
Dave A., Maru L., Jain A. LDH (Lactate Dehydrogenase): A Biochemical Marker for the Prediction of Adverse Outcomes in Pre-eclampsia and Eclampsia. 
Journal of Obstetrics and Gynecology of India 2016 01 Feb 2016;66(1):23-29 
Oztas E., Ozler S., Ersoy A.O., Iskender C.T., Sucak A., Ergin M., et al. Increased levels of serum clusterin is associated with intrauterine growth restriction and 
adverse pregnancy outcomes in preeclampsia. J.Perinat.Med. 2016 01 Apr 2016;44(3):269-275 
Tumanyan S.S., Tumanyan S.V., Rymashevski AN. Predictors of renal dysfunction and its correction in women with preeclampsia and alimentary obesity. 
Anesteziol.Reanimatol. 2015 01 Jan 2015;60(1):42-44 
 
Combined maternal and fetal outcomes (N=12) 
1. Allotey J, Marlin N, Mol BW, et al. Development and validation of prediction models for risk of adverse outcomes in women with early-onset pre-eclampsia: 
Protocol of the prospective cohort PREP study. Diagnostic and Prognostic Research. 2017;1(1). doi: 10.1186/s41512-016-0004-8. Parrish M., Griffin M., 2. 
Morris R., Darby M., Owens M.Y., Martin Jr. JN. Hyperuricemia facilitates the prediction of maternal and perinatal adverse outcome in patients with 
severe/superimposed preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine 2010 December 2010;23(12):1451-1455 
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 3. Robb A., Elia E., Hemming K., Price M., Riley R., FrenchConstant A., et al. Could urinary albumin: Creatinine ratio be used to predict adverse outcomes in 
suspected preeclampsia?. BJOG: An International Journal of Obstetrics and Gynaecology 2016. April 2016;123:17 
4. van der Tuuk K, Koopmans CM, Groen H, Aarnoudse JG, van den Berg PP, van Beek JJ, et al. Prediction of progression to a high risk situation in women 
with gestational hypertension or mild pre-eclampsia at term. Aust.N.Z.J.Obstet.Gynaecol. 2011 Aug;51(4):339-346 
5. De Oliveira L., Peracoli J.C., Peracoli M.T., Korkes H., Zampieri G., Moron A.F., et al. SFlt-1/PlGF ratio as a prognostic marker of adverse outcomes in 
women with early-onset preeclampsia. Pregnancy Hypertension 2013 July 2013;3(3):191-195 
6. Lumbanraja SN. Determining the maternal characteristics that predicts the adverse outcomes for patients with preeclampsia. Journal of Health and 
Translational Medicine 2013 2013;16(1):1-6 
7. Moore A.G., Young H., Keller J.M., Ojo L.R., Yan J., Simas T.A.M., et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in 
suspected preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine 2012 December 2012;25(12):2651-2657 
8. Nadeau H.C., Tita A.T.N., Anderson S., Tang Y., Dimperio L., Harper LM. Predicting adverse pregnancy outcomes associated with chronic hypertension: A 
classification and regression tree (CART) Analysis. American Journal of Obstetrics and Gynecology.Conference: January 2016;214(1 SUPPL. 1):S245 
9. Rana S., Hacker M., Merport A., Salahuddin S., Verlohren S., Perschel F., et al. Angiogenic factors and risk of preeclampsia related adverse outcomes in twin 
pregnancies. Pregnancy Hypertension 2012. July 2012;2(3):273-274 
10. Robb A., Elia E., Hemming K., Price M., Riley R., FrenchConstant A., et al. Could urinary albumin: Creatinine ratio be used to predict adverse outcomes in 
suspected preeclampsia?. BJOG: An International Journal of Obstetrics and Gynaecology 2016. April 2016;123:17 
11. Sibiude J., Guibourdenche J., Dionne M.D., Le Ray C., Anselem O., Serreau R., et al. Placental Growth Factor for the Prediction of Adverse Outcomes in 
Patients with Suspected Preeclampsia or Intrauterine Growth Restriction. PLoS ONE 2012;7(11) (pagination):Arte Number: e50208. ate of Pubaton: 28 No 2012 
12. Chaiworapongsa T, Romero R, Korzeniewski SJ, Cortez JM, Pappas A, Tarca AL, et al. Plasma concentrations of angiogenic/anti-angiogenic factors have 
prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: A prospective study. Journal of maternal-fetal  
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S4. Characteristics of included studies, N = 32 studies  
INDEPENDENT STUDIES, N=28 studies 
Author, Year Study design Country(ies) Time period Type of HDP Maternal 
characteristics 
Outcome(s) Prediction 
method 
Tests 
Ankumah et al. 
2014  
Multicentre 
RCT 
USA May 1991-
Jun 1995 
Mild chronic 
hypertension 
Mean age: 30 
Mean GA: 19.8 
Nulliparous: 18.2% 
Placental abruption Univariable Blood pressure 
Aziz et al. 2011 Retrospective 
review 
India Jan 2005- 
Dec 2009 
HELLP 
syndrome 
 
 
Mean age: 26.6 
Mean GA: 32.9 
Nulliparity: 62.2%  
 
 
 
Composite:  
DIC, ARF, PPH, Placental 
abruption, cerebral 
or pulmonary edema, 
liver infarcts or rupture, 
or a subcapsular 
liver hematoma or 
maternal death 
Univariable Epigastric pain; 
vomiting; headache; 
visual symptoms; non-
specific viral 
symptoms; platelets; 
AST; ALT; LDH 
Ben Salem et 
al. 2003 
Case-control Tunisia Jan 1995- 
Jun 2000 
Pre-eclampsia 
 
Mean age: 30 
NulliParity: 38.3% 
Eclampsia 
 
Univariable sBP; dBP; headache; 
visual symptoms; 
hyperreflexia; 
proteinuria; uric acid; 
serum creatinine; AST 
Bouzari et al. 
2014 
Retrospective 
cohort 
Iran 2000-2010 Pre-eclampsia 
 
Mean age: 29.5 Placental abruption Univariable 24h proteinuria 
Chan et al. 
2005 
Retrospective 
cohort 
Australia 1998-2001 Pre-eclampsia 
 
Mean Age: 30 
Nulliparity:  73% 
Composite:  
renal insufficiency 
(creatinine >90 umol/L), 
liver disease 
(AST >40 U/L), cerebral 
irritation 
(hyperreflexia with clonus 
or repeated visual 
scotomata, 
requiring magnesium 
sulphate) and 
thrombocytopenia 
(platelets <150*  10
9
/L) 
 
Multivariable 
logistic 
regression 
Spot urine PRCR and 
maternal age at 
diagnosis 
Gangaram et Prospective South Africa January Gestational Median GA: 33 Composite: Placental Univariable Spot urine ACR 
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al. 2009 cohort 2006 hypertension 
and pre-
eclampsia 
Nulliparity: 12.9% 
 
abruption, eclampsia 
 
Ghosh et al. 
2012 
Prospective 
cohort 
India Mar 2009- 
Jun 2011 
Early onset 
preeclampsia 
<34 weeks 
 
GA presentation: 23 
Median Age: 23 
Nulliparity: 76% 
Postpartum hemorrhage 
(PPH) defined as a blood  
loss of >1500 ml and/or 
the need for a blood 
transfusion, 
for a caesarian delivery 
and >1000 ml and/or the 
need for a blood 
transfusion, in case of a 
vaginal birth 
Univariable Serum PlGF 
Girling et al. 
1997 
Prospective 
cross-sectional 
UK - Pre-eclampsia GA presentation: -
Mean age: 29 
 
 
Composite: 
acute renal failure 
requiring dialysis, 
profound oliguria needing 
central venous pressure 
monitoring and renal 
support, and 
spontaneous pulmonary 
oedema 
Multivariable Abnormal liver function 
tests (AST, ALT, 
bilirubin, GGT) 
Hall et al. 2002 Prospective 
cohort 
South Africa Apr 1992 – 
Mar 1997 
Early onset, 
severe pre-
eclampsia 
 
Mean Age: 27 
Mean GA: 29.5 
Placental abruption, 
ascites, pulmonary 
edema, eclampsia 
Univariable 24h proteinuria 
Kozic et al. 
2011 
Multicentre 
prospective 
review 
Canada, 
Australia, 
New Zealand, 
UK 
Sep 2003 – 
Jan 2010 
Pre-eclampsia  Mean: 31 
Nulliparity: 71.1% 
PIERS Composite Univariable AST, ALT, LDH, albumin, 
total bilirubin, INR 
Laskin et al. 
2011 
Multicentre 
prospective 
cohort 
Canada, New 
Zealand, 
Australia, UK 
Sep 2003 – 
Jan 2010 
Pre-eclampsia 
 
Median age: 31 
Median GA: 33.7 
Nulliparity: 72.6% 
PIERS composite outcome Univariable Platelet count 
Leaños-
Miranda et al. 
2013 
Prospective 
cohort 
Mexico - Pre-eclampsia GA presentation: 32 
Mean Age: 28.3 
Nulliparous: 43.5% 
Composite: maternal 
mortality 
and any of the following 
serious maternal 
morbidities: hepatic 
Univariable Serum sFlt-1/PlGF ratio 
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hematoma or rupture 
(confirmed by ultrasound 
or laparotomy), 
pulmonary 
edema (clinical diagnosis 
and with radiographic 
confirmation), 
need for positive 
inotropic support, 
intubation (other than 
solely for 
caesarean section), acute 
renal failure (creatinine 
≥198 μmol/L), and 
placental abruption 
(clinical or pathological). 
Livingston et 
al. 2014 
Multicentre 
prospective 
cohort 
Canada, New 
Zealand, 
Australia, UK 
Sept 2003 – 
Dec 2011 
Pre-eclampsia Median Age: 31 
Median  GA: 35 
Nulliparity: 73.8% 
PIERS composite outcome Univariable Uric acid 
Millman et al. 
2011 
Multicentre 
prospective 
cohort 
Canada, New 
Zealand, 
Australia, UK 
Sept 2003 – 
Jan 2010 
Pre-eclampsia 
 
Median Age: 31 
Median GA:34.1 
Nulliparity: 89.2% 
PIERS composite outcome Univariable 
and 
multivariable 
SpO2; chest pain and/or 
dyspnea 
Palomaki et al. 
2015 
Prospective 
cohort 
USA Jul 2009 – 
Jun 2012 
HDP 
 
Mean GA: 30 
 
Composite (Placental 
abruption, 
Acute renal failure, 
DIC, 
Pulmonary edema) 
Univariable sFlt-1/PlGF ratio 
Payne et al. 
2011 
Multicentre 
prospective 
cohort 
Canada, New 
Zealand, 
Australia, UK 
Sept 2003 – 
Jan 2010 
Pre-eclampsia 
 
Median age: 31 
Median GA: 36 
Nulliparity: 71.4% 
PIERS composite outcome Univariable Proteinuria (dipstick, 
spot PRCR, 24h protein) 
Payne et al. 
2014 
Multicentre 
prospective 
cohort 
Uganda, 
South Africa, 
Brazil, 
Pakistan 
Jul 2008 – 
Mar 2012 
Any HDP 
 
Median age: 28 
Median GA: 35.3 
Nulliparity: 46.1% 
 
PIERS composite outcome Multivariable 
logistic 
regression 
Parity, GA at 
assessment, chest 
pain/dyspnea, 
headache/visual 
disturbances, vaginal 
bleeding with 
abdominal pain, sBP, 
dipstick proteinuria 
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Payne et al. 
2015 
Multicentre 
prospective 
cohort 
South Africa, 
Pakistan 
Jan 2011 – 
Dec 2013 
All HDP Mean age: 28 
Nulliparity: 47.7% 
PIERS composite outcome Multivariable 
logistic 
regression 
Parity, 
GA at assessment, 
Chest pain/dyspnea, 
Headache/visual 
disturbances, Vaginal 
bleeding with 
abdominal pain,  
sBP,  
dipstick proteinuria and 
SpO2 
Rana  et al. 
2013 
Prospective 
cohort 
USA Jul 2009 – 
Oct 2010 
Pre-eclampsia Mean Age: 32 
Mean GA: 35  
Nulliparity: 70.1% 
Composite: abnormal 
liver function test and 
platelets, placental 
abruption, pulmonary 
edema, cerebral 
hemorrhage, seizure (in 
the absence 
of an underlying seizure 
disorder), acute renal 
failure 
(creatinine41.5mg/dL) 
or maternal death 
Spearman 
rank 
correlation 
sFlt1/PlGF ratio 
Romero et al. 
1988 
Retrospective 
review 
USA Jan 1981 – 
Sep 1984 
GH, Pre-
eclampsia and 
superimposed 
pre-eclampsia 
Mean age: 25.5 
Nulliparity:  71.6% 
Pulmonary edema, 
eclampsia  
Univariable AST 
Saleh et al. 
2016 
Prospective Netherlands 
 
Sep 2011 – 
Aug 2013 
Pre-eclampsia 
 
Mean age: 32 
Mean GA: 30  
Composite: 
Pulmonary edema, 
Acute renal failure 
Binary logistic 
analysis 
sFlt1/PlGF ratio 
Scazzochio et 
al. 2013 
Prospective Spain Sep 2010 – 
Sep 2012 
Severe 
preeclampsia  
<34 weeks 
Mean age: 32 
Mean GA: 30.3 
Primiparity: 58.2% 
Composite:  
Acute renal failure and 
pulmonary edema 
Univariable Maternal Neutrophil 
Gelatinase-Associated 
Lipocalin (NGAL) 
Schiff et al. 
1996 
Retrospective 
review 
USA Jan 1990 – 
Dec 1994 
Severe pre-
eclampsia 
 
Mean Age: 23 
Mean GA: 31.2 
Nulliparity: 50% 
Placental abruption Univariable 24h urine proteinuria 
von Dadelszen 
et al. 2011 
Multicentre 
prospective 
cohort 
Canada, New 
Zealand, 
Australia, UK 
Sep 2003 – 
Jan 2010 
Pre-eclampsia Median age: 31 
Median GA: 35 
Nulliparity: 71.3% 
PIERS composite outcome Multivariable 
logistic 
regression 
GA,  
Chest pain or 
dyspnoea, oxygen 
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saturation, platelet 
count, creatinine, and 
AST 
Witlin et al. 
1999 
 
Prospective USA Mar 1992 – 
Jan 1997 
Severe pre-
eclampsia 
Mean Age: 22.8 Eclampsia, placental 
abruption 
Univariable Mean arterial pressure 
(MAP), 
Platelet count  
Yassaee et al. 
2003 
Cohort Iran 1986-2001 Severe pre-
eclampsia 
- Maternal mortality, 
eclampsia 
Univariable Uric acid 
Yen et al. 2011 Multicentre 
prospective 
cohort 
Canada, New 
Zealand, 
Australia, UK 
Sep 2003 – 
Jul 2009 
Pre-eclampsia Mean Age: 32  
Mean GA: 34.4  
Nulliparity: 71.3% 
PIERS composite outcome Univariable  
 
Nausea and vomiting; 
Headache; 
Visual disturbances; 
Right upper quadrant 
or epigastric pain; 
Abdominal pain or 
vaginal bleeding; 
Chest pain or dyspnea 
Yucesoy et al. 
2005 
Prospective 
cohort 
Turkey - HELLP 
syndrome 
Mean age: 26.5  
Mean GA: 31.5 
Nulliparity: 29.5% 
Eclampsia, placenta 
abruption, DIC, acute 
renal failure, maternal 
mortality 
Univariable  
 
Platelet count 
EXTERNAL VALIDATION STUDIES, N=4 studies 
Author, Year Study design Country(ies) Time period Type of HDP Maternal 
characteristics 
Outcome(s) Primary study Case-mix compared to 
primary study 
von Dadelszen 
et al. 2011 
Multicentre 
prospective 
cohort 
Canada, New 
Zealand, 
Australia, UK 
Sep 2003 – 
Jan 2010 
Pre-eclampsia Median age: 31 
Median GA: 35 
Nulliparity: 71.3% 
PIERS composite outcome Primary model 
being 
externally 
validated 
Only pre-eclampsia in 
high-income countries, 
all GAs, tertiary 
centres, expectant 
management 
Agrawal et al. 
2014 
Prospective 
cohort 
India - Pre-eclampsia Mean GA: 24.8 
Nulliparity: 48.6% 
PIERS composite von Dadelszen 
et al. 2011 
Low- and middle-
income countries 
(LMICs) 
Akkermans et 
al.  
2014 
Multicentre 
prospective 
cohort 
Netherlands Apr 2000 – 
May 2003 
Severe early-
onset pre-
eclampsia, 
eclampsia, 
HELLP 
syndrome or 
Mean age: 29.5 
Mean GA: 30.3 
Nulliparity: 69.9% 
PIERS composite von Dadelszen 
et al. 2011 
GA <34 weeks, high-
risk cohort only 
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hypertension-
associated 
fetal growth 
restriction  
Hadley et al.  
2016* 
Retrospective 
cohort 
USA - Pre-eclampsia - PIERS composite von Dadelszen 
et al. 2011 
Conservative 
management 
Ukah et al.  
2015 
Prospective 
cohort 
USA Jul 2008 – 
Mar 2012 
Any HDP Median age: 28 
Median GA: 35.3 
Nulliparity: 46.1% 
PIERS composite von Dadelszen 
et al. 2011 
Any HDPs, LMICs 
* Abstract only with limited information  
ACR (albumin:creatinine ratio); ALT (alanine transaminase); ARF (acute renal failure); AST (aspartate transaminase); dBP (diastolic blood pressure); DIC 
(disseminated intravascular coagulation); GA (gestational age); GGT (gamma-glutamyl transferase); HDPs (hypertensive disorders of pregnancy); INR 
(international normalized ratio); LDH (lactate dehydrogenase); LMICs (low- and middle-income countries); MAP (mean arterial pressure); NGAL (neutrophil 
gelatinase-associated lipocalin); PIERS (pre-eclampsia integrated estimate of risk); PlGF (placental growth factor); PPH (postpartum haemorrhage); PRCR 
(protein:creatinine ratio); RCT (randomized controlled trial); RUQ (Right upper quadrant pain); sBP (systolic blood pressure); SD (standard deviation); sFlt-1 
(soluble fms-like tyrosine kinase-1); SpO2 (oxygen saturation)  
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S5. Quality of included studies scores 
Study Population 
selection 
Appropriat
e study 
design 
Complete 
follow 
up/withdrawal
s explained 
Appropriat
e patient 
spectrum 
Test 
descriptio
n 
Handlin
g of 
missing 
data 
Outcome 
descriptio
n 
Sampl
e size  
Internal 
Validatio
n 
External 
validatio
n 
Scor
e 
Agrawal 2015 1 1 0 0 1 0 1 0 0 0 4 
Akkermans 
2014 
1 1 1 0 1 1 1 0 0 0 6 
Ankumah 2014 1 1 1 1 1 1 1 0 0 0 7 
Aziz  
2011 
1 0 0 1 1 0 1 0 0 0 4 
Ben Salem 2003 1 0 1 0 1 0 1 0 0 0 4 
Bouzari 2014 1 0 1 1 1 1 1 0 0 0 6 
Chan  
2005 
1 0 1 1 1 0 1 0 0 0 5 
Gangaram 2009 1 1 1 1 1 0 1 0 0 0 6 
Ghosh  
2012 
1 1 0 1 1 0 1 0 0 0 5 
Girling 1997 1 1 0 1 1 0 1 0 0 0 5 
Hadley 2016 1 1 0 1 0 0 1 0 0 0 4 
Hall  
2002 
1 1 0 1 1 0 1 0 0 0 5 
Kozic  1 1 1 1 1 0 1 0 0 0 6 
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2011 
Laskin 2011 1 1 0 1 1 0 1 0 0 0 5 
Leaños-
Miranda 2013 
1 1 0 1 1 0 1 0 0 0 5 
Livingston 2014 1 1 1 1 1 1 1 0 0 0 7 
Millman 2011 1 1 0 1 1 0 1 0 0 0 5 
Palomaki 2015 1 1 1 1 1 1 1 1 0 0 8 
Payne  
2015 
(miniPIERS + 
SpO2) 
1 1 0 1 1 1 1 1 1 0 8 
Payne  
2011 
(proteinuria) 
1 1 1 1 1 1 1 0 0 0 7 
Payne  
2014  
(miniPIERS) 
1 1 1 1 1 1 1 1 1 1 10 
Rana  
2013 
0 1 0 0 1 0 1 0 0 0 3 
Romero 1988 1 0 1 1 1 1 1 0 0 0 6 
Saleh 2016 1 1 0 1 1 0 1 1 0 0 6 
Scazzochio 2013 1 1 1 1 1 1 1 0 0 0 7 
Schiff  
1996 
1 1 0 1 1 0 1 0 0 0 5 
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Ukah  
2015 
1 1 0 0 1 0 1 1 0 0 5 
von Dadelszen 
2011 
1 1 1 1 1 1 1 1 1 1 10 
Witlin  
1999 
1 1 0 1 1 0 1 0 0 0 5 
Yassaee 2003 1 0 0 0 1 0 1 0 0 0 3 
Yen  
2011 
1 1 0 1 1 0 1 0 0 0 5 
Yucesoy 2005 1 1 0 1 1 0 1 0 0 0 5 
 
Assessment Questions: 1 = Yes; 0 = No; Score: <4 = High risk of bias; 4-6 = Medium risk of bias; ≥7 = Low risk of bias 
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S6. Multivariable model variable coefficients 
Study name Model variables Coefficients AUROC 
Chan 2005 Spot urine protein/creatinine 0.003 0.67 
(0.55-0.71) Age 0.058 
Girling 1997 ALT Not stated - 
AST 
Bilirubin 
GGT 
Millman 
2011 
chest pain and/or dyspnea 1.404 0.73 
(0.67-0.78) Oxygen saturation −0.362 
Payne 2014  
(miniPIERS) 
multiparity -0.298 0.79 
(0.74–0.80) GA -1.07 
Chest pain/dyspnea 0.847 
Headache or visual symptoms 0.422 
Vaginal bleeding with 
abdominal pain 
1.18 
sBP 1.34 
dipstick proteinuria -0.218 
Payne 2015  
(miniPIERS + SpO2) 
Oxygen saturation 
+ miniPIERS variables 
 
−0.434 
+ miniPIERS 
0.81 
(0.76-0.86) 
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von Dadelszen 2011 
(fullPIERS) 
GA -0.054 0·88 
(0·84–0·92) Chest pain or dyspnoea,  1.23 
platelet count 0.207 
creatinine  -0.027 
AST 0.010 
Oxygen saturation 0.03681 
Creatinine *platelets 0.00025 
Platelets*AST -0.000069 
Platelets* oxygen saturation -0.0026 
Platelets2 0.00004 
AST2 -0.0000031 
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S7. PRISMA checklist 
Section/topic  # Checklist item  Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
1 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3-4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
3-4 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
4 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
4 & S4 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
5 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
S2 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
5 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
6 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
5-6 & S1 
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Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
6 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  6 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
6-7 
 
Section/topic  # Checklist item  Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
N/A 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
N/A 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
7 & Fig1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
7-8 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  8-9 & S4 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
9 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  10-13 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  N/A 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  12 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
13-15 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
16 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  16 
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Page 1 of 2  
 
*From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
Page 2 of 2  
 
 
 
 
 
 
 
  
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
17 
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Additional records identified 
through other sources (citation) 
(n = 35 ) 
Records after duplicates removed  
(n = 1118) 
Title and Abstracts 
screened  
(n = 1117 ) 
Records excluded  
(n = 965) 
Full-text articles assessed 
for eligibility 
(n = 153) 
Full-text articles excluded 
 (n = 121) 
 
• Not a test accuracy study = 89 
• Reviews and comments = 11 
• Combined HDP and outcome 
= 6 
• 2*2 table not possible = 3 
• Combined maternal and fetal 
outcome = 12 
Studies included in 
synthesis  
(n = 32) 
Figure 1. PRISMA flow diagram showing study selection process  
  
 
Figure 2. Quality assessment of the included studies 
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HIGHLIGHTS 
• The ability to predict maternal outcomes from HDPs will guide management of such pregnancies 
• We have systematically reviewed potential predictors of severe maternal complications among women with all types of HDPs 
including both univariable and multivariable tests  
• Multivariable models perform better than do individual tests in predicting adverse maternal outcomes from the HDPs.  
• Potential tests to consider in multivariable models are: gestational age, headache, visual symptoms, chest pain, dyspnea, 
oxygen saturation, and AST,  
• There is need for better quality studies in prediction and combination of predictors for better chances of prediction of adverse 
maternal outcomes. 
 
 
